Pfizer announced that its investigational biologic PF-06410293 met the primary endpoint in the comparative REFLECTIONS B538-02 study by demonstrating equivalent efficacy as measured by the American College of Rheumatology 20 (ACR20) response rate at Week 12 to Humira (adalimumab; AbbVie, US). In the trial, Humira and PF-06410293 were administered in combination with methotrexate in patients with moderate-to-severe rheumatoid arthritis.